BR112013023773B8 - Composição imunogênica para modulação do sistema imune e seu uso no tratamento de câncer - Google Patents

Composição imunogênica para modulação do sistema imune e seu uso no tratamento de câncer

Info

Publication number
BR112013023773B8
BR112013023773B8 BR112013023773A BR112013023773A BR112013023773B8 BR 112013023773 B8 BR112013023773 B8 BR 112013023773B8 BR 112013023773 A BR112013023773 A BR 112013023773A BR 112013023773 A BR112013023773 A BR 112013023773A BR 112013023773 B8 BR112013023773 B8 BR 112013023773B8
Authority
BR
Brazil
Prior art keywords
diseases
treatment
regeneration
present
prevention
Prior art date
Application number
BR112013023773A
Other languages
English (en)
Other versions
BR112013023773B1 (pt
BR112013023773A2 (pt
Inventor
Eduardo Nowill Alexandre
Original Assignee
Eduardo Nowill Alexandre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eduardo Nowill Alexandre filed Critical Eduardo Nowill Alexandre
Publication of BR112013023773A2 publication Critical patent/BR112013023773A2/pt
Publication of BR112013023773B1 publication Critical patent/BR112013023773B1/pt
Publication of BR112013023773B8 publication Critical patent/BR112013023773B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)

Abstract

COMPOSIÇÃO IMUNOGÊNICA PARA MODULAÇÃO DO SISTEMA IMUNE E SEU USO, MÉTODO DE TRATAMENTO E PREVENÇÃO DE DOENÇAS, MÉTODO PARA INDUZIR A REGENERAÇÃO CELULAR E MÉTODO PARA RECONDUÇÃO DA RESPOSTA IMUNE A presente invenção refere-se a composições imunogênicas para modulação do sistema imune que compreendem uma quantidade terapeuticamente eficaz de dois ou mais agentes antigênicos imunoativos que apresentam padrões moleculares associados a patógenos (PAMPS) e / ou padrões moleculares associados a perigo (DAMPS) e um ou mais dentre um veículo, excipiente, diluente ou solvente fisiologicamente aceitável. As composições imunogênicas da presente invenção são utilizadas na manufatura de medicamentos para prevenção e / ou tratamento de e na prevenção e / ou tratamento de doenças infecciosas, doenças autoimunes, doenças alérgicas, inflamações, artrites, doenças inflamatórias, rejeição de transplantes, afecções causadas por distúrbios vasculares, doenças provocadas por acidentes cardiovasculares hemorrágicos ou isquêmicos, isquemia, infarto e hemorragias que levam a destruição dos tecidos, insuficiência cardíaca, renal, respiratória ou hepática, câncer, tumores e neoplasias malignas e benignas. A presente invenção refere-se ainda a métodos para induzir a regeneração celular, regeneração de tecidos, regeneração de órgãos e regeneração de sistemas orgânicos, tais como o sistema circulatório, o sistema nervoso e o sistema endócrino. Por último a presente invenção refere-se a métodos para recondução da resposta imune em um animal, particularmente humanos.
BR112013023773A 2011-03-18 2012-03-19 Composição imunogênica para modulação do sistema imune e seu uso no tratamento de câncer BR112013023773B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI1100857-1A BRPI1100857A2 (pt) 2011-03-18 2011-03-18 agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
BRPI1100857-1 2011-03-18
PCT/BR2012/000072 WO2012122618A1 (pt) 2011-03-17 2012-03-19 Composição imunogênica para modulação do sistema imune e seu uso, método de tratamento e prevenção de doenças, método para induzir a regeneração celular e método para recondução da resposta imune

Publications (3)

Publication Number Publication Date
BR112013023773A2 BR112013023773A2 (pt) 2020-11-10
BR112013023773B1 BR112013023773B1 (pt) 2022-09-20
BR112013023773B8 true BR112013023773B8 (pt) 2022-10-18

Family

ID=46829971

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1100857-1A BRPI1100857A2 (pt) 2011-03-17 2011-03-18 agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
BR112013023773A BR112013023773B8 (pt) 2011-03-18 2012-03-19 Composição imunogênica para modulação do sistema imune e seu uso no tratamento de câncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI1100857-1A BRPI1100857A2 (pt) 2011-03-17 2011-03-18 agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real

Country Status (16)

Country Link
US (1) US9566330B2 (pt)
EP (1) EP2687227B1 (pt)
JP (2) JP6181636B2 (pt)
KR (1) KR102008535B1 (pt)
CN (1) CN103717233B (pt)
AU (1) AU2012229902B2 (pt)
BR (2) BRPI1100857A2 (pt)
CA (1) CA2837348A1 (pt)
CL (1) CL2013002712A1 (pt)
CO (1) CO6831973A2 (pt)
DK (1) DK2687227T3 (pt)
ES (1) ES2699264T3 (pt)
MX (1) MX363050B (pt)
PT (1) PT2687227T (pt)
RU (1) RU2678317C2 (pt)
WO (1) WO2012122618A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213504B2 (en) 2011-03-18 2019-02-26 Alexandre Eduardo Nowill Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SG11201510150VA (en) 2013-06-21 2016-01-28 Ondek Pty Ltd Immunotherapy composition and use thereof
PE20170298A1 (es) 2014-03-28 2017-04-18 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico del cancer de prostata
KR101631312B1 (ko) * 2014-06-16 2016-06-20 연세대학교 산학협력단 재조합 람블편모충 결합 면역글로블린 단백질을 포함하는 면역증강 조성물
CN104546937B (zh) * 2014-09-30 2019-02-01 深圳华大基因科技有限公司 系结梭菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
HUE037476T2 (hu) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polipeptid és immunmodulálás
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
PT3253800T (pt) 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59308B1 (sr) 2015-06-15 2019-10-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EP3636272A1 (en) 2015-06-15 2020-04-15 4D Pharma Research Limited Compositions comprising bacterial strains
LT3650033T (lt) 2015-06-15 2022-04-11 4D Pharma Research Limited Kompozicijos, apimančios bakterinius kamienus
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB2561748B (en) 2015-11-20 2019-05-08 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
TW201733601A (zh) 2016-03-04 2017-10-01 ４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
IL268626B2 (en) * 2017-02-13 2024-04-01 Alexandre Eduardo Nowill Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
MD3638271T2 (ro) 2017-06-14 2021-03-31 4D Pharma Res Ltd Compoziții cuprizând tulpini bacteriene
DK3804737T3 (da) 2017-06-14 2022-07-25 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
RU2699540C2 (ru) * 2017-08-17 2019-09-06 Павел Павлович Несмиянов Композиция, содержащая пробиотические бактерии или их компоненты, и способ ее применения в лечении иммунных заболеваний кожи
AU2019215191A1 (en) * 2018-02-02 2020-09-17 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
CN109010824A (zh) * 2018-08-27 2018-12-18 广州汇高生物科技有限公司 一种特异性卵黄免疫球蛋白组合物及其制剂
WO2020106158A1 (en) * 2018-11-20 2020-05-28 Acd Pharmaceuticals As Serratia liquefaciens variant
ES2962407T3 (es) * 2018-12-04 2024-03-18 Sabiotec Spin Off S L Inmunoestimulante para su uso contra patógenos
CN110156885B (zh) * 2019-05-23 2020-11-24 南京林业大学 松材线虫的病原相关模式分子蛋白BxCDP1及其应用
WO2022040768A1 (en) * 2020-08-28 2022-03-03 Nowill Alexandre Eduardo Compositions for uses in methods of treating coronavirus infections
CN113244273A (zh) * 2021-03-16 2021-08-13 广州中科蓝华生物科技有限公司 疟原虫在制备联合放射疗法用于抗肿瘤的制剂中的应用
CN114606317B (zh) * 2022-03-22 2022-12-02 中山大学附属第一医院 一种预测胃癌***转移的菌群标志物及其应用
DE202023103094U1 (de) 2023-06-06 2023-06-30 Dasari Chandransh Ein System zur Regeneration menschlicher Zellen mit isoliertem regenerativem Gen eines Planarienorganismus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
SI1659178T1 (sl) * 1998-02-05 2010-07-30 Glaxosmithkline Biolog Sa Postopek za čiščenje ali proizvodnjo MAGE proteina
US6432710B1 (en) * 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2004096270A1 (en) * 2003-04-30 2004-11-11 Medi Service S.R.L. Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
WO2005077408A2 (en) * 2004-02-06 2005-08-25 Vaxinnate Corporation Compositions of pamps and listeria monocytogenes and methods of use
PL1765391T3 (pl) * 2004-06-07 2013-08-30 Qu Biologics Inc Kompozycje bakteryjne do leczenia nowotworów
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
EP2977456B1 (en) * 2006-08-15 2017-10-25 The Trustees Of The University Of Pennsylvania Compositions comprising hmw-maa and fragments thereof for treating cancer
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
WO2009073133A1 (en) * 2007-11-29 2009-06-11 Vaxinnate Corporation Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof
EP2303236A4 (en) * 2008-07-01 2012-09-26 Univ Emory SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US20120093855A1 (en) * 2008-11-18 2012-04-19 Ligocyte Pharmaceuticals, Inc. RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF

Also Published As

Publication number Publication date
EP2687227A4 (en) 2014-10-01
JP2014508783A (ja) 2014-04-10
RU2013143400A (ru) 2015-04-27
KR102008535B1 (ko) 2019-10-21
ES2699264T3 (es) 2019-02-08
US20140037716A1 (en) 2014-02-06
WO2012122618A8 (pt) 2012-11-08
EP2687227A1 (en) 2014-01-22
BRPI1100857A2 (pt) 2013-05-21
AU2012229902A1 (en) 2013-11-07
MX2013010669A (es) 2014-10-14
CN103717233B (zh) 2020-05-26
CA2837348A1 (en) 2012-09-20
JP2017132776A (ja) 2017-08-03
RU2678317C2 (ru) 2019-01-28
PT2687227T (pt) 2018-12-11
BR112013023773B1 (pt) 2022-09-20
WO2012122618A1 (pt) 2012-09-20
DK2687227T3 (en) 2018-12-10
MX363050B (es) 2019-03-06
CN103717233A (zh) 2014-04-09
CL2013002712A1 (es) 2014-08-18
NZ616823A (en) 2016-08-26
JP6181636B2 (ja) 2017-08-16
EP2687227B1 (en) 2018-08-22
BR112013023773A2 (pt) 2020-11-10
US9566330B2 (en) 2017-02-14
CO6831973A2 (es) 2014-01-10
KR20140027162A (ko) 2014-03-06
AU2012229902B2 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
BR112013023773B8 (pt) Composição imunogênica para modulação do sistema imune e seu uso no tratamento de câncer
BR112015021222A2 (pt) inibidores de ras e usos dos mesmos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015022588A2 (pt) composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
ECSP14000357A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
NZ729643A (en) Combination therapy for treating cancer
BR112015002755A8 (pt) Derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico e uso de derivados
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
BR112013024907A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2698 DE 20/09/2022, QUANTO AO ITEM (54) TITULO.